Roger Wellington-Oguri

Roger Wellington-Oguri

Auto-generated profile, based on publicly available information

Roger Wellington-Oguri

Eterna massive open laboratory

Research Focus & Metrics

Academic Career Length

53Years (1974-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2022 in Nature Communications
Verified
Journal Article
Open access
KLKathrin Leppek
Kathrin Leppek
GBGun Woo Byeon
Gun Woo Byeon
WKWipapat Kladwang
Wipapat Kladwang
HWHannah K. Wayment-Steele
Hannah K. Wayment-Steele
CKCraig H. Kerr
Craig H. Kerr
RDRhiju Das
Rhiju Das
Therapeutic mRNAs and vaccines are being developed for a broad range of human diseases, including COVID-19. However, their optimization is hindered by mRNA instability and inefficient protein expression. Here, we describe design principles that overcome these barriers. We develop an RNA sequencing-based platform called PERSIST-seq to systematically delineate in-cell mRNA stability, ribosome load, as well as in-solution stability of a library of diverse mRNAs. We find that, surprisingly, in-cell stability is a greater driver of protein output than high ribosome load. We further introduce a method called In-line-seq, applied to thousands of diverse RNAs, that reveals sequence and structure-based rules for mitigating hydrolytic degradation. Our findings show that highly structured “superfolder” mRNAs can be designed to improve both stability and expression with further enhancement through pseudouridine nucleoside modification. Together, our study demonstrates simultaneous improvement of mRNA stability and protein expression and provides a computational-experimental platform for the enhancement of mRNA medicines.

14 September 2021 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
HWHannah K Wayment-Steele
Hannah K Wayment-Steele
DKDo Soon Kim
Do Soon Kim
CCChristian A Choe
Christian A Choe
JNJohn J Nicol
John J Nicol
RWRoger Wellington-Oguri
Roger Wellington-Oguri
RDRhiju Das
Rhiju Das
RNA hydrolysis presents problems in manufacturing, long-term storage, world-wide delivery and in vivo stability of messenger RNA (mRNA)-based vaccines and therapeutics. A largely unexplored strategy to reduce mRNA hydrolysis is to redesign RNAs to form double-stranded regions, which are protected from in-line cleavage and enzymatic degradation, while coding for the same proteins. The amount of stabilization that this strategy can deliver and the most effective algorithmic approach to achieve stabilization remain poorly understood. Here, we present simple calculations for estimating RNA stability against hydrolysis, and a model that links the average unpaired probability of an mRNA, or AUP, to its overall hydrolysis rate. To characterize the stabilization achievable through structure design, we compare AUP optimization by conventional mRNA design methods to results from more computationally sophisticated algorithms and crowdsourcing through the OpenVaccine challenge on the Eterna platform. We find that rational design on Eterna and the more sophisticated algorithms lead to constructs with low AUP, which we term ‘superfolder’ mRNAs. These designs exhibit a wide diversity of sequence and structure features that may be desirable for translation, biophysical size, and immunogenicity. Furthermore, their folding is robust to temperature, computer modeling method, choice of flanking untranslated regions, and changes in target protein sequence, as illustrated by rapid redesign of superfolder mRNAs for B.1.351, P.1 and B.1.1.7 variants of the prefusion-stabilized SARS-CoV-2 spike protein. Increases in in vitro mRNA half-life by at least two-fold appear immediately achievable.

1 December 1977 in Journal of Educational Measurement
Verified
Journal Article
Closed access
PDF file
KSKenneth Sirotnik
Kenneth Sirotnik
RWRoger Wellington
Roger Wellington

30 March 2021 in bioRxiv
Verified
Preprint
Open access
KLKathrin Leppek
Kathrin Leppek
GBGun Woo Byeon
Gun Woo Byeon
WKWipapat Kladwang
Wipapat Kladwang
HWHannah K. Wayment-Steele
Hannah K. Wayment-Steele
CKCraig H. Kerr
Craig H. Kerr
RDRhiju Das
Rhiju Das
SUMMARY: Therapeutic mRNAs and vaccines are being developed for a broad range of human diseases, including COVID-19. However, their optimization is hindered by mRNA instability and inefficient protein expression. Here, we describe design principles that overcome these barriers. We develop a new RNA sequencing-based platform called PERSIST-seq to systematically delineate in-cell mRNA stability, ribosome load, as well as in-solution stability of a library of diverse mRNAs. We find that, surprisingly, in-cell stability is a greater driver of protein output than high ribosome load. We further introduce a method called In-line-seq, applied to thousands of diverse RNAs, that reveals sequence and structure-based rules for mitigating hydrolytic degradation. Our findings show that “superfolder” mRNAs can be designed to improve both stability and expression that are further enhanced through pseudouridine nucleoside modification. Together, our study demonstrates simultaneous improvement of mRNA stability and protein expression and provides a computational-experimental platform for the enhancement of mRNA medicines.

1 September 1976 in Psychometrika
Verified
Journal Article
Closed access
PDF file
RWRoger Wellington
Roger Wellington
Generalized symmetric means are redefined in a way which allows them to be calculated for any matrix sampling design. It is proved that these sample gsm's are unbiased estimates of the analogous population gsm's. Illustrative examples are given.

30 September 2021 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
HWHannah K Wayment-Steele
Hannah K Wayment-Steele
DKDo Soon Kim
Do Soon Kim
CCChristian A Choe
Christian A Choe
JNJohn J Nicol
John J Nicol
RWRoger Wellington-Oguri
Roger Wellington-Oguri
RDRhiju Das
Rhiju Das
The authors wish to correct the supplementary data in their article ( 1).